Clark, CR; DeRuiter, J. Analytical and synthetic studies on designer drugs of the piperazine class, US DOJ, 1 Dec 2014. 15.6 MB. #4-ClPP MS
Adamowicz, P; Zuba, D. Discrimination among designer drug isomers by chromatographic and spectrometric methods In Chromatographic Techniques in the Forensic Analysis of Designer Drugs; Kowalska, T; Sajewicz, M; Sherma, J, Eds., CRC Press, Taylor & Francis Group, 1 Jan 2018; pp 211–232. 1.1 MB. LC,MS,IR,UV
Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #4CPP GC,LC,MS,UV
EMCDDA. New drugs in Europe, 2006, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2007. 375 kB. #pCPP
Okamoto, K; Akimoto, S; Ando, T; Ikeda, Y; Kurashima, N. Differentiation of regioisomeric analogs of controlled substances using GC-IR JCCL, 1 Oct 2016, (56), 49–70. 4.5 MB. #4CPP Japanese, English abstract GC,MS,IR
Clancy, L; Philp, M; Shimmon, R; Fu, S. Development and validation of a color spot test method for the presumptive detection of 25-NBOMe compounds Drug Test. Anal., 19 Aug 2020, 13 (5), 929-943. 11.3 MB. https://doi.org/10.1002/dta.2905 #1-(4-chlorophenyl)-piperazine spot
Doi, K; Miyazawa, M; Fujii, H; Kojima, T. The analysis of the chemical drugs among structural isomer Yakugaku Zasshi, 1 Sep 2006, 126 (9), 815–823. 371 kB. https://doi.org/10.1248/yakushi.126.815 #4CPP GC,LC,MS,NMR,IR,TLC
Philp, M; Shimmon, R; Stojanovska, N; Tahtouh, M; Fu, S. Development and validation of a presumptive colour spot test method for the detection of piperazine analogues in seized illicit materials Anal. Methods, 1 Jan 2013, 5 (20), 5402. 783 kB. https://doi.org/10.1039/c3ay40511g #1-(4-Chlorophenyl)piperazine (pC MS,NMR,IR,spot
Schoenwald, RD; Gadiraju, RR; Barfknecht, CF. Serotonin antagonists for use as antiglaucoma agents and their ocular penetration Eur. J. Pharm. Biopharm., 1 Jun 1997, 43 (3), 273–281. 688 kB. https://doi.org/10.1016/S0939-6411(97)00055-6 #4